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Abstract
Background: Adopting technologies such as injection safety devices in healthcare settings can enhance injection
safety. Developing guidelines for appropriate adoption of such technologies need to consider factors beyond
evidence for their health effects. The objective of this study is to systematically review the published literature for
evidence among healthcare workers and patients about knowledge, attitudes, beliefs, values, preferences, and
feasibility in relation to the use of injection safety devices in healthcare settings.
Methods: We included both qualitative and quantitative studies conducted with the general public, patients, and
healthcare workers, administrators, or policy makers. We searched MEDLINE, EMBASE, CINHAL and CENTRAL. We
used a duplicate and independent approach to title and abstract screening, full text screening, data abstraction and
risk of bias assessment.
Results: Out of a total of 6568 identified citations, we judged fourteen studies as eligible for this systematic review.
All these studies were surveys, conducted with healthcare workers in high-income countries. We did not identify
any qualitative study, or a study of the general public, patients, healthcare administrators or policy makers. We did
not identify any study assessing knowledge, or values assigned to outcomes relevant to injection safety devices.
Each of the included studies suffered from methodological limitations, which lowers our confidence in their
findings. Based on the findings of six studies, the injection safety devices were generally perceived as easy to use
and as an improvement compared with conventional syringes. Some of these studies reported few technical
problems while using the devices. In three studies assessing perceived safety, the majority of participants judged
the devices as safe. Two studies reported positive perceptions of healthcare workers regarding patient tolerance of
these injection safety devices. One study found that less than half the nurses felt comfortable using the insulin
pens. Findings from four studies assessing preference and satisfaction were not consistent.
Conclusions: This systematic review identified evidence that injection safety devices are generally perceived as
easy to use, safe, and tolerated by patients. There were few reports of technical problems while using the devices
and some discomfort by nurses using the insulin pens.
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Background
According to the World Health Organisation (WHO),
there were 3 million exposures amongst healthcare
workers (HCWs) in 2002 to blood borne pathogens due
to needlestick injuries (NSI) [1]. The major pathogens of
concern are hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immunodeficiency virus (HIV).
Amongst HCWs, it is estimated that 37 % of Hepatitis B
virus (HBV) infections, 39 % of Hepatitis C virus (HCV)
infections, and 4.4 % of Human Immunodeficiency virus
(HIV) infections are due to needlestick injuries [2]. NSI
have also the potential to transmit other infectious
agents, such as viral hemorrhagic fever viruses. Similarly,
in the year 2000, the reuse of injection equipment
accounted for 32, 40, and 5 % of new HBV, HCV, and
HIV infections worldwide [1]. These infections will lead
to a burden of 9.18 million disability-adjusted life years
(DALYs) between the years 2000 and 2030 [3].
Adopting injection safety devices such as sharp injury
protection (SIP) devices and reuse prevention (RUP) de-
vices can enhance injection safety. The first stage of
introducing an injection safety device into the clinical
setting however, is an assessment of user acceptability
[4]. These evaluations are usually conducted within a
short timeframe and provide valuable information re-
garding user’s preferences and product characteristics
[5]. Unfortunately, policies and guidelines for injection
safety practices lack for a number of countries.
We conducted this study in preparation for the
development of WHO policy guidance on use of
injection safety devices by healthcare workers. The
development of WHO policy guidance follows the
GRADE methodology [6, 7]. The methodology calls
for the consideration of factors beyond evidence for
their health effects, including the valuation of the
outcomes of interest, the preference for the different
management options, their feasibility, and their effect
on equity [6]. The consideration of these factors
should be ideally based on a systematic review of the
available evidence.
The objective of this study is to systematically review
the published literature for evidence among healthcare
workers and patients about knowledge, attitudes,
beliefs, values, preferences, and feasibility in relation to
the use of injection safety devices in healthcare
settings.
Methods
In this article, the term injection broadly refers to the
use of sharp device in delivering skin injection or venous
and arterial access for medication delivery and phlebot-
omy. We developed a protocol for this systematic review
and registered it with PROSPERO [8].
Eligibility criteria
Types of study designs
We included the following types of study designs:
 Quantitative studies including surveys
 Qualitative studies including individual interviews,
and focus groups.
 Other study designs that specifically assess values
and preferences including: time trade-off, probability
trade-off, treatment trade-off, standard gamble, and
visual analogue scales.
 Studies examining choices made when presented
with decision aids
 Decision analyses
We excluded scientific meeting abstracts and research
letters.
Types of study participants
We included studies conducted with the following types
of participants:
 General public
 Patients with or without history of blood-borne
infections due to injection in healthcare settings
 Healthcare workers with or without history of
needle stick injury
 Healthcare administrators
 Healthcare policy makers (including those in the
health insurance industry)
Types of settings
We included studies about the use of injection safety
devices in the healthcare setting, i.e., healthcare
workers delivering injections and patients receiving
those injections for any reason (i.e., preventive, thera-
peutic, family planning). We were not interested in
studies conducted in non-healthcare settings (e.g.,
illicit drug use, patients using insulin pen needles at
home).
Types of injection devices
We were interested in both sharp injury protection de-
vices and/or reuse prevention devices. We included
studies assessing intramuscular (IM), subcutaneous (SC),
intradermal (ID), phlebotomy and intravenous (IV)injec-
tions. Eligible injection safety devices included:
 Retractable needle device
 Needle shields, and recapping devices
 Needleless injectors
 Needle-safety devices
 Devices used for reconstitution methods which have
a needle shield
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 Auto-disable syringes (earlier called “auto-destruct
syringes”), typically meant for vaccination
 Reuse prevention devices
 Pre-filled devices with reuse prevention feature
 Intravenous devices with a needle protection
attribute
 IV catheters with a needle protection attribute
 All blood collection devices (lancet devices, vacuum
tubes for blood collection devices, an arterial blood
syringes).
We excluded studies using devices with needle protec-
tion attribute for articular, intra cardiac, and intra peri-
toneal injections.
Types of outcome measures
We included studies that assessed the following outcomes:
 Knowledge related to use of injection safety devices
in healthcare settings;
 Attitudes and beliefs towards use of injection safety
devices in healthcare settings;
 Values assigned to outcomes relevant to use of
injection safety devices in healthcare settings (e.g.,
HIV infection). In other words, how much do those
affected value the outcome?
 Preferences regarding the use of injection safety
devices in healthcare settings;
 Feasibility of use of injection safety devices in
healthcare settings. In other words, is it feasible to
sustain the use of the device and to address
potential barriers to implementing it?
Literature search
We electronically searched (from date of inception to
October 2013), the following databases used the OVID
interface: MEDLINE, EMBASE, CINHAL and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL). We did not use language or date restrictions.
Additional file 1 lists the search strategy used in Med-
line. We also reviewed the references lists of relevant pa-
pers, searched of personal files for both published and
unpublished stud2es and contacted experts.
Selection process
Two teams of two reviewers each screened titles and ab-
stracts of identified citations in duplicate and independ-
ently. We obtained the full texts of citations judged by at
least one reviewer as potentially eligible. We conducted
calibration exercises prior to screening in order to clarify
the process. The two review teams screened the full
texts for eligibility using a duplicate and independent ap-
proach and a standardized and pilot tested form. They
resolved disagreements by discussion or with the help of
a third reviewer when needed.
Data abstraction process
A third review team abstracted data from eligible studies
in duplicate and independent manner for English articles.
For one non-English article, one reviewer abstracted the
data. They used a standardized and pilot tested data ab-
straction form with detailed instructions. They resolved
disagreements by discussion or with the help of a third re-
viewer when needed.
The abstracted data items included:
 Funding and reported conflicts of interest.
 Methodology including: type of study, survey
instrument, sampling frame, sampling method,
recruitment method, and survey administration
method.
 Methodological quality. As there is no widely
accepted tool for assessing the methodological
quality of surveys, we abstracted information about
the following: sample size calculation, sampling type,
validity of tool, pilot testing, response rate, and
handling of missing data.
 Population including: type, sample size, age, and
gender.





We planned to report the results separately for two
groups of devices: (1) intramuscular, subcutaneous, and
intradermal injections; and (2) phlebotomy, and intra-
venous devices. This separation reflected the WHO ex-
pert panel decision to address these types separately in
relation to their use in the clinical setting. We reported
the statistical results for each study separately. We
planned on stratifying results based on the type of par-
ticipants/population (e.g., healthcare workers, patients)
and based on the type of outcome assessed.
Results
Please note that the use and mentioning of trade names
in this article represents no endorsement of or advertise-
ment for any product. The use of trade names was un-
avoidable as no generic names were identified for the
devices evaluated here.
Study selection
Figure 1 shows the study flow. Out of a total of 6569
identified citations, we judged fourteen as eligible for
this systematic review [4, 9–21]. Of these, six studies
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reported data specific to subcutaneous, intramuscular, or
intradermal injection safety devices [4, 9, 12, 13, 16, 17].
Seven studies reported data specific to intravenous or
phlebotomy safety devices [10, 11, 14, 15, 18, 19, 21].
The fourteenth study reported data on any of the above
types of devices [20].
Table 1 provides the list of the 14 excluded studies
with the following reasons for exclusion: 7 of the studies
did not assess an injection safety device [22–28], 3 stud-
ies were not conducted in a healthcare setting [29–31],
3studies reported attitudes of patients injecting them-
selves [32–34], and one study did not report on any of
the outcomes of interest [35].
Study characteristics
Additional file 2 provides the characteristics of the in-
cluded studies about subcutaneous, intramuscular, or
intradermal injection safety devices. Additional file 3
provides the characteristics of the included studies about
intravenous or phlebotomy safety devices.
Methodology
We did not identify any qualitative study. The included
studies used a survey methodology using questionnaires.
Four of these studies used 5-point or 10-point Likert scales
[4, 9, 13, 16]. One study used a 7-point Likert scale [11].
There was poor reporting of the studies’ sampling frame,
recruitment method, survey administration method, and
sampling method. Vaudelle-Malbos et al. reported using
convenience sampling, [20] Adams et al. reported a ran-
dom selection of participants, [4], Adams et al. and
Rivers et al. reported randomly selecting nurses [9, 19].
Prunette et al. reported cluster sampling [18].
Methodological quality
None of the studies reported sample size calculation.
Three reported using a probability sampling approach
Fig. 1 Study flow diagram
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[4, 9, 20]. Vaudelle-Malbos et al. reported non-
probability sampling [20]. None of the other studies re-
ported on sampling type. Davis et al. mentioned that the
questionnaire used was based on “previously published
validated and non-validated surveys” [12]. Butler et al.
mentioned that the questionnaire used was adapted from
a previously developed one for a new device question-
naire, and the validity was not reported [11]. Pilot testing
was done in two studies [11, 19]. None of the
remaining studies reported whether their question-
naires were pilot tested or validated. Eight studies re-
ported on their response rates, which ranged from 5 %
[20] to 100 % [4, 16]. None of the included studies re-
ported on the handling of missing data. All these meth-
odological limitations lower our confidence in the
findings reported by those studies.
Devices
The devices assessed in the included studies were:
 Eclipse™, SafetyGlide™ and SafetyGlide™ insulin [4].
 SafetyGlide™hypodermic needles, SafetyGlide™-TNT
(Tiny Needle Technology) insulin units and blunt fill
cannulae [9].
 FlexPen®, and InnoLet® [12].
 Eclipse™, Magellan™, and SecureGard™ [13].
 Although the device brand was not reported, the
injection safety device was described as having “a
plastic sheath that extends over the needle tip to
prevent accidental needle stick injuries. However, a
spring-loaded plastic sheath covers the needle when
a button is pushed with one finger. Thus, the safety
feature is engaged with one hand after use” [16].
 Becton Dickinson 3 ml Safety-Lok™ syringe,and
BaxterInterLink® needless intravenous system [17].
 Safety-Lok™, and Needle Pro®, Protectiv®I.V.
catheter, and 2 needleless systems (Interlink® and
Bionecteur®) [20].
 Needle-free system of all plastic material [15].
 Safety-Lok™, Punctur-Guard®, Venipuncture
Needle-Pro® [22].
 BIO-SET®, double spike reconstruction device [29].
 Eclipse™, QuickShield® and Push Button™ [23].
 Introcan Safety® catheters, Insyte Autoguard™ [24].
 Protectiv® Plus IV [19].
 Clearlink ®needless connector [21].
Study funding
Of the seven included studies assessing subcutaneous,
intramuscular, or intradermal injection safety devices,
three reported their funding source, where two men-
tioned it as Becton Dickinson(Oxford, UK), [4, 9] and
the other as Baxter Healthcare Corporation [17]. Of the
seven included studies assessing intravenous and phle-
botomy safety devices, three reported their funding
source to be respectively: Department of Anesthesiology,
Military Teaching Hospital Sainte Anne, Toulon, France;
[18] Lamar University, Beaumont, Texas [19] Baxter
Healthcare corporation [21].
Conflict of interest
One study reported that one author had conflict of inter-
est with Novo.
Nordisk [12]. One study reported that their authors
had no conflicts of interest [13]. The remaining studies
did not provide conflicts of interest disclosures.
Population
Populations of thirteen studies included nursing popula-
tions, eight of which included physicians [4, 10, 14, 16–
18, 20, 21]. One study did not describe its participant
population [13]. The sample size of these studies ranged
between 17 and 1705 participants. We did not identify
any study of the general public, patients, healthcare ad-
ministrators or policy makers.
Setting
Six of the studies were conducted in the United States
[10, 11, 15–17, 19]. Two in France, [18, 20] Five in the
United Kingdom, [4, 9, 13, 14, 21]. One study did not
specify the country where it was conducted, but it ap-
pears to have been conducted in the United States [12].
All studies were conducted in the healthcare setting. We
did not identify any study conducted in a low or middle-
income country.
Table 1 List of excluded studies and reasons for exclusion
Study Reason for exclusion
English, 1992 [22] Study did not assess an injection safety device
Guerlain 2010 [29] Study was not conducted in a health care setting
Hirayama 2009 [23] Study did not assess an injection safety device
Jeanes 1999 [24] Study did not assess an injection safety device
Kuroyama 2006 [25] Study did not assess an injection safety device
Lee 2005 [35] Study did not report on any of the outcomes
of interest
Musso 2010 [32] Study reported attitudes of patients injecting
themselves
Oyer 2011 [26] Study did not assess an injection safety device
Pfutzner 2013 [27] Study did not assess an injection safety device
Quiroga1998 [30] Study was not conducted in a health care setting
Shelmet 2004 [33] Study reported attitudes of patients injecting
themselves
Sibbitt 2008 [28] Study did not assess an injection safety device
Tsu 2009 [31] Study was not conducted in a health care setting
Vidovic 2010 [34] Study reported attitudes of patients injecting
themselves
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Outcomes assessed
The outcomes assessed included the following: per-
ceived ease of use, perceived safety, perceived patient
tolerance, perceived compatibility, reliability, confi-
dence, preference, and satisfaction. One study assessed
the predictors of acceptance of the device [19]. We
did not identify any study assessing knowledge, or
assigned to outcomes relevant to injection safety
devices.
Findings
We present below a summary of the findings of the in-
cluded studies in relation to the each of the assessed
outcomes. We first report the results relevant to IM, SC
and ID injections, based on seven of the fourteen studies
[4, 9, 12, 13, 16, 17, 20]. We then report the results rele-
vant to IV/Phlebotomy devices based on eight of the
fourteen studies [10, 11, 14, 15, 18–21].
Intramuscular, subcutaneous and intradermal safety
injections devices
Perceived ease of use
Six studies assessed ease of use and reported the follow-
ing findings: [4, 9, 12, 13, 17, 20]
 3 ml Safety-Lok™ was considered simple to use,
and not associated with significantly more
operator time [17].
 Safety-Lok™ was perceived as very easy to use,
but with minor difficulties concerning the
insertion of needle and obligation of one
attempt [20].
 Between 70 % and 80 % of nurses agreed that
FlexPen® and InnoLet® insulin pens were more
convenient, simple and easy to use, and were an
overall improvement compared with conventional
vials/syringes [12].
 Most respondents felt that the SecureGard™
device required both hands to activate it [13].
One participant did not like putting the thumb
near the needle tip to activate the Eclipse™ device,
and other users made similar points about putting
fingers near the tip of the Magellan™ device
during activation [13].
 Eclipse™, SafetyGlide™ and SafetyGlide™ insulin
were on average perceived as easy to activate,
intuitive to use, did not hinder routine use, did
not require more time to use than conventional
products and did not require detailed training
to use [4].
 In the study assessing SafetyGlide™ needles,
SafetyGlide™-TNT insulin units, staff considered
that the devices to be usable and compatible with
most clinical situations [9].
Perceived safety
Three studies assessed perceived safety and reported the
following findings: [4, 9, 20]
 Safety-Lok™, and Needle Pro® devices were perceived
as safe. On third of users thought that the Needle-
Pro device was not effective in avoiding needlestick
injuries and therefore should not be implemented as
a injection safety device [20].
 Eclipse™, SafetyGlide™ and SafetyGlide™ insulin were
perceived to meet the safety standard, allowed
activation to be clearly designated, could not be
deactivated when reasonable force was applied [4].
 In the study assessing SafetyGlide™ needles,
SafetyGlide™-TNT insulin units, staff considered that
the devices to be safe [9].
Perceived patient tolerance
Two of the studies assessed patient tolerance towards
the injection safety devices used and reported the follow-
ing findings: [13, 16]
 The “safety syringes” (described as having a plastic
sheath that extends over the needle tip) were
perceived as comfortable [16].
 Eclipse™, Magellan™ and the SecureGard™ devices
were not more painful to the patient compared to
conventional devices [13].
Perceived compatibility
In one study, the safety feature of Eclipse™, Safety-
Glide™ and SafetyGlide™ insulin were not perceived,
on average, to hinder the product’s use. Only 6 % of
nurses were concerned whether devices could be used
for phlebotomy [4].
Reliability
Different users raised a number of reliability issues re-
garding the SecureGard™ product (e.g., leakage on one
occasion, accidental activation of the device, needles fall-
ing off, safety feature not activating accurately on every
occasion) [13].
Confidence
In the study assessing FlexPen® and InnoLet® insulin
pens, 45 % of nurses agreed that they felt more comfort-
able giving insulin, using the pens compared with the
conventional method [12]. Thirty nine percent of nurses
agreed that they felt more confident they were giving the
correct dose of insulin using pens compared with the
conventional method [12].
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Preference and satisfaction
Four studies assessed perceived preference or satisfac-
tion of HCWs regarding the use of the devices and re-
ported the following findings: [12, 13, 16, 17]
 Positive findings for FlexPen® and InnoLet® insulin
pen devices [12]. Specifically, the nurses agreed that
insulin pens were more convenient and that it took
less time to prepare and administer insulin;
 Negative findings for the 3 ml Safety-Lok™ syringe.
This was reportedly related to difficulty in engaging
the protective sheath and because its size after being
sheathed impeded easy disposal in needle boxes; [17].
 In one study, the shielded devices (Magellan™ and
Eclipse™) were preferred over the retractable devices
(SecureGard™), with Magellan being favored by most
users [13].
 The overall satisfaction with the unspecified “safety
syringe” was unfavorable, with lower median
responses for post-use questions [16].
Phlebotomy and intravenous injections devices
Perceived ease of use
Four studies [10, 14, 15, 18] assessed ease of use and re-
ported the following findings:
 Seventy three percent said that Safety-Lok™,
Punctur-Guard™, Venipuncture Needle-Pro were
easier to use than the conventional device. Fifty
eight percent said they facilitated the procedure,
31 % said they made the procedure more difficult,
and 10 % were unsure [10].
 Concerning the Eclipse™, QuickShield® and Push
Button™ some users indicated that certain
orientations make it uncomfortable to hold the
devices and perform venipuncture, while others
indicated that shields could visually obstruct the
needle.
Results from the evaluations of the Push Button™
set were positive, i.e., the device was perceived
easy to use.
Some users commented that they did not like the
position of the shield on the QuickShield and others
stated that it was bulky, cumbersome and difficult to
engage [14].
 Intensive care and critical care staff felt that the all-
plastic material IV needle free system (anonymous
brand) required too much manipulation and was too
time consuming. Personnel were concerned that
needle-free system would limit the fast flow rates
during surgery [15].
 The passive Introcan® safety catheter was more
efficient than the active Insyte Autoguard® safety
catheter with regard to the ease of introducing the
catheter into the vein and the staff ’s exposure to the
patient’s blood.
The withdrawal of the needle was more difficult in
the passive Introcan® Safety device group compared
with the Vialon® and the active Insyte Autoguard®
groups [19].
 A positive response (measured as ease of use) was
given of more than 85 %, regarding the usability of
the needless connector [21].
Perceived safety
Four studies [10, 18–20] assessed perceived safety and
reported the following findings:
 The catheter Protectiv® was not safe to use [20].
 Sixty seven percent reported that the vacuum tube
blood-collection needle with recapping sheath made
the procedures safer to perform, 52 % reported that
the bluntable vacuum tube blood-collection needle
(Venipuncture Needle-Pro®) was safe, and 56 %
reported that the resheathable winged steel needle
device (Safety-Lok™) was safe [10].
 Ninety two percent agreed that proper use of the
device protects from needlestick injury [19].
 The staff ’s sense of protection against the risk of an
accidental needlestick was equal and more favorable
with the safety catheters (passive safety Introcan®
Safety catheters, active safety Insyte Autoguard®)
than with the conventional catheter (Vialon®, the
nonsafety IV catheter) [18].
1. In the study assessing Clearlink®needless
connector, 70 % preferred to use the safer
sharps device rather than a conventionally used
luer cap [21].
Perceived compatibility
Three studies [14, 15, 21] assessed perceived safety and
reported the following findings:
 Compared with the Eclipse™, fewer users felt that
the QuickShield® should be considered for use in the
Welsh NHS or would consider using it instead of a
conventionally used blood evacuation needle [14].
 Eighty nine percent of the nurses thought that the
needle free all-plastic material IV system (brand not
specified) was the answer to the IV-related needle
punctures [15].
 Eighty five percent of health care workers
considered the Clearlink®needless connector to be
suitable for every day practice [21].
Confidence
Three studies assessed the confidence perceived using
the IV injection safety devices: [14, 19, 21].
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In the study assessing Eclipse™, QuickShield® and Push
Button™, more users appeared to be comfortable using
the Eclipse™ than the QuickShield. Most users found the
Push Button™ set comfortable to use [14].
Eighty six percent of nurses mentioned that they will
always use Protectiv Plus® IV device where eighty three
percent felt comfortable using Protectiv Plus® IV [19].
In the study assessing the needless connector, 85 % of
health care workers felt confident to use the device after
caring for 3 patients [21].
Reliability
Eight percent reported having difficulty to avoid leak of
blood after removal of needle from the vein using the
Protectiv® IV catheter [20].
In the study assessing the needless connector Clear-
link®, only 1respondent noted a tendency for the device,
to ‘pop off ’ when used with a luer lock syringe [21].
Predictors of acceptance
In the study assessing the Protectiv Plus® IV [19],
they assessed the individual and organizational predic-
tors of acceptance of the device by nurses. Almost
half of the nurses (48.6 %) had used the device more
than 12 months. The majority of nurses (69.6 %)
agreed to the appropriateness of time between train-
ing and use of device. The majority (76.9 %) dis-
agreed that they needed more time for training. The
authors mentioned that a positive safety climate
existed, referring specifically the fast training suggest-
ing considerable acceptance of the device between
nurses [19].
Preference and satisfaction
Five studies [10, 11, 14, 15, 19] assessed perceived
preference or satisfaction of HCWs regarding the use
of the devices and reported the following findings:
 Fifty seven percent favored phlebotomy needle with
recapping sheath (Safety-Lok™), 26 % favored
bluntable phlebotomy needle (Punctur-Guard®), and
47 % favored resheathable winged steel needle
compared with the respective conventional devices.
Twenty three percent of respondents had no
preference [10].
1. Nurses scored the needless device Bioset almost
twice as high as conventional method non safety
on total preference [11].
 The Eclipse product was favored slightly more than
the QuickShield (the two being phlebotomy safety
devices) [14].
 Ninety five percent of the nurses responded that an
unspecified IV system was preferred to other needle-
free systems evaluated [15].
 Seventy six percent of nurses agreed that they are
generally satisfied with the Protectiv-R Plus® IV
device [19].
Discussion
In summary, this systematic review identified evidence
from fourteen studies suggesting that injection safety de-
vices are generally perceived as easy to use, safe, and tol-
erated by patients. There were few reports of technical
problems while using the devices and some discomfort
by nurses using the insulin pens. Nurses’ preferences
and satisfaction were not consistent in studies related to
intramuscular, subcutaneous and intradermal injections.
Unfortunately, the included studies suffered from meth-
odological limitations, which lowers our confidence in
their findings.
In one study, the appropriate use of an injection safety
device with “a plastic sheath that extends over the needle
tip” was reported to be suboptimal (at most 60 %), even
after an educational presentation [16]. That same paper
described the challenge of activating the safety feature
through additional steps that require time, effort, and
depend on whether the user remembers to perform the
task. In another study, the authors described the passive
Introcan safety catheter as more efficient than the active
Insyte Autoguard safety catheter with regard to the ease
of introducing the catheter into the vein and the staff ’s
exposure to the patient’s blood [16]. These findings high-
light the importance of educational intervention, buy-in,
and use of simplified devices, such as passive rather than
active injection safety devices [16].
This study has a number of limitations and strengths.
The limitations are mainly related to the small number
and low quality of the available evidence. In addition, we
did not identify any qualitative study and none of the in-
cluded studies was conducted in low or middle-income
countries or included the general public, patients,
healthcare administrators or policy makers. We did not
identify any study assessing knowledge, or values
assigned to outcomes relevant to injection safety devices.
It is important to note that we did not include studies
relevant to articular, intra cardiac, and intra peritoneal
injection devices. The main strength of this study relates
to the use of standard approaches in conducting [36],
and reporting systematic reviews [37].
We have identified one other systematic review, pub-
lished by the Health and Safety Laboratory for the
Health and Safety Executive 2012, [38] addressing
whether the use of injury prevention devices in health-
care affect user acceptability compared to standard prac-
tices. The results of that review were consistent with
ours and they concluded that “health care workers
should be involved in the evaluation of products before
any safer sharps device is introduced” and that “user
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acceptability is likely to be an obstacle to the uptake of
safer sharps devices”. That review included only five
studies potentially relevant to our question, all of which
we have identified and included in this review [4, 10, 18,
19, 21]. They included two studies that we think are not
eligible for our review. They missed to include nine
other studies that we judged as eligible and have in-
cluded in our review [9, 11–17, 20].
Conclusions
Our findings have implications for clinical practice.
Healthcare workers perceive injection safety devices to
be generally easy to use, safe, and tolerated by patients.
It is not clear whether some of the reported technical
problems, and the extra steps required for using the in-
jection safety devices explain the inconsistency between
the included studies in preferences and satisfaction.
There is a need to engage healthcare workers in the se-
lection of the injection safety devices to ensure user ac-
ceptability and the eventual desired beneficial effect on
disease burden.
Our findings have also research implications. Future
research should include qualitative studies to better
understand the findings above. There is also a need to
conduct studies low or middle-income countries, and
studies assessing knowledge, and values assigned to out-
comes relevant to injection safety.
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